Organization TC 1600 Bldg./Room RI UNITED STATES PATENT AND TRADEMARK OFFICE

P.O. Box 1450 Alexandria, VA. 22313-1450 If Undeliverable Return In Ten Days

Official Business
Penalty For Private Use, \$300

AN EQUAL OPPORTUNITY EMPLOYER



RECEIVED

TECH CENTER 1600/2900

98 6958X89056

A CONTRACTOR OF THE PARTY OF TH

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

26619

7590

04/19/2004

DELTAGEN, INC. 740 BAY ROAD REDWOOK CITY, CA 94063 EXAMINER

SULLIVAN, DANIEL M

ART UNIT

PAPER NUMBER

1636

DATE MAILED: 04/19/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
00/004 190	07/11/2001	Keith D. Allen	R-477	1187

TITLE OF INVENTION: TRANSGENIC MICE CONTAINING STEFIN HOMOLOG PROTEASE INHIBITOR GENE DISRUPTIONS

1	APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	j
	nonprovisional	YES	\$665	\$300	\$965	07/19/2004	

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.
- ☐ Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or Fax

(703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where

appropriate. All further corr indicated unless corrected b maintenance fee notification	elow or directed otherwise	atent, advance orders and a in Block 1, by (a) specifying	notification of maintenance in ng a new correspondence	address; and/or (b) indicating a sep	parate "FEE ADDRESS" for
CURRENT CORRESPONDENCE	E ADDRESS (Note: Legibly mark-up	with any corrections or use Block 1)	Fee(s) Transm papers. Each a	icate of mailing can only be used to ittal. This certificate cannot be used additional paper, such as an assignm	ient or formal drawing, must
DELTAGEN, INC 740 BAY ROAD REDWOOK CITY	C.		I hereby certif States Postal S addressed to t	crtificate of mailing or transmission. Certificate of Mailing or Tran by that this Fee(s) Transmittal is bein cervice with sufficient postage for fi the Mail Stop ISSUE FEE address the USPTO, on the date indicated be	nsmission ng deposited with the United rst class mail in an envelope s above, or being facsimile
					(Depositor's name)
					(Signature)
					(Date)
APPLICATION NO.	FILING DATE	FIRST NA	MED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/904,180	07/11/2001		th D. Allen	R-477	1187
TITLE OF INVENTION: TI	RANSGENIC MICE CONTA	AINING STEFIN HOMOLO	OG PROTEASE INHIBITO	OR GENE DISRUPTIONS	
		legue err	PUBLICATION FE	EE TOTAL FEE(S) DUE	DATE DUE
APPLN. TYPE	SMALL ENTITY	ISSUE FEE	\$300	\$965	07/19/2004
nonprovisional	YES	\$665	\$300	\$703	0111912004
EXAM	INER	ART UNIT	CLASS-SUBCLAS	SS	
SULLIVAN,	DANIEL M	1636	800-018000	•	
□ "Fee Address" indicati PTO/SB/47; Rev 03-02 on Number is required. 3. ASSIGNEE NAME AND	d to the USPTO or is being s	ion form e of a Customer E PRINTED ON THE PAT low, no assignee data will a submitted under separate co	mager on the notent Includ	is listed, no name 3ion of assignee data is only appropring NOT a substitute for filing an as	riate when an assignment has signment.
Please check the appropriate	assignee category or catego			al corporation or other private	group entity
4a. The following fee(s) are	enclosed:	· ·- 3 · · ·	nt of Fee(s): eck in the amount of the fee	(c) is enclosed	·
☐ Issue Fee ☐ Publication Fee			ent by credit card. Form PT	• •	
Advance Order - # of	Copies	☐ The I	Director is hereby authoriz	ed by charge the required fee(s), o	r credit any overpayment, to copy of this form).
Director for Patents is reque	sted to apply the Issue Fee a		Account Numberor to re-apply any previous	ly paid issue fee to the application ic	
(Authorized Signature)		(Date)	1		
other than the applicant; interest as shown by the re	d Publication Fee (if requir a registered attorney or ag cords of the United States Pa	ent; or the assignee or oth atent and Trademark Office.	ner party in		
This collection of information obtain or retain a benefit application. Confidentialit estimated to take 12 minu completed application for case. Any comments on suggestions for reducing Patent and Trademark 22313-1450. DO NOT SEED TRADE TO STATE T	ation is required by 37 CFR by the public which is to fi y is governed by 35 U.S.C. 1	1.311. The information is ile (and by the USPTO to 22 and 37 CFR 1.14. This	required to process) an		



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	. FII	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/904,180 07/11/2001 Keith D. Allen 26619 7590 04/19/2004		7/11/2001	Keith D. Allen	R-477	1187
		EXAMINER			
DELTAGEN, INC.				SULLIVAN, DANIEL M	
740 BAY ROAD REDWOOK CITY, CA 94063		063		ART UNIT	PAPER NUMBER
		·	1636		
				DATE MAILED: 04/19/2004	1

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

	Application No.	Applicant(s)			
	09/904,180	ALLEN, KEITH D.			
Notice of Allowability	Examiner	Art Unit			
	Daniel M Sullivan	1636			
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS erewith (or previously mailed), a Notice of Allowance (PTOL-85) HOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIFE of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this or other appropriate communica GHTS. This application is subje and MPEP 1308.	application. If not included tion will be mailed in due course. THIS ct to withdrawal from issue at the initiative			
	<u>Nequest for Continued Examinat</u>	ion nieu s January 2004 .			
2. ☑ The allowed claim(s) is/are <u>1-5,8-11,20,22 and 24</u> .					
3. ☑ The drawings filed on <u>28 October 2002</u> are accepted by the	e Examiner.				
 Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 	been received.				
Copies of the certified copies of the priority documents have	• •				
International Bureau (PCT Rule 17.2(a)).		по положа осадо арриодают поли ало			
* Certified copies not received:					
Applicant has THREE MONTHS FROM THE "MAILING DATE" onted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		ply complying with the requirements			
5. A SUBSTITUTE OATH OR DECLARATION must be submi INFORMAL PATENT APPLICATION (PTO-152) which give					
S. CORRECTED DRAWINGS (as "replacement sheets") mus	t be submitted.				
(a) ☐ including changes required by the Notice of Draftspers	,	TO-948) attached			
1) hereto or 2) to Paper No./Mail Date					
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date .	s Amendment / Comment or in th	ne Office action of			
Identifying indicia such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the	84(c)) should be written on the drage header according to 37 CFR 1.1	awings in the front (not the back) of I21(d).			
DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.					
•					
Attachment(s)					
. Notice of References Cited (PTO-892)	<u> </u>	al Patent Application (PTO-152)			
. Notice of Draftperson's Patent Drawing Review (PTO-948)	6.				
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 					
. Examiner's Comment Regarding Requirement for Deposit	8. Examiner's State	ement of Reasons for Allowance			
of Biological Material	9. Other				
		Anne-Marie Falk			
		ANNE-MARIE FALK, PH.D PRIMARY EXAMINER			

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04) Application/Control Number: 09/904,180

Art Unit: 1636

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Robert Driscoll on 1 April 2004.

The application has been amended as follows:

Claims 9 and 10 have been replaced with the following amended claims:

- 9. A cell derived isolated from the transgenic mouse of claim 8.
- 10. A method of producing a transgenic mouse comprising a genome comprising a disruption in an endogenous stefin homolog gene comprising SEQ ID NO: 1, the method comprising:
 - (a) introducing the targeting construct of claim 1 into a mouse embryonic stem cell;
 - (b) selecting a cell which has undergone homologous recombination;
 - (c) introducing the cell into a blastocyst;
 - (e)(d) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
 - (d)(e) breeding the chimeric mouse to produce the transgenic mouse wherein where the disruption is homozygous, the transgenic mouse lacks production of functional protein encoded by the stefin homolog gene and exhibits, relative to a wild-type mouse, a

Application/Control Number: 09/904,180

Art Unit: 1636

phenotype selected from the group consisting of: increased activity, schizophrenic behavior, and decreased propensity for despair or depression.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel M Sullivan whose telephone number is 571-272-0779. The examiner can normally be reached on Monday through Thursday 6:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

DMS

ANNE-MARIE FALK, PH.D. PRIMARY EXAMINED

Anne-Marie Falk

	Application No.	Applicant(s)					
The state of the s	09/904,180	ALLEN, KEITH D.					
Examiner-Initiated Interview Summary	Examiner	Art Unit					
_	Daniel M Sullivan	1636					
All Participants:	Status of Application: <u>All</u>	<u>owed</u>					
(1) <u>Daniel M Sullivan</u> .	(3)						
(2) Robert Driscoll.	(4)						
Date of Interview: <u>1 April 2004</u>	Time:						
Type of Interview: ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative) Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:							
Part I.							
Rejection(s) discussed:							
Claims discussed:							
9, 10							
Prior art documents discussed:							
Part II.							
SUBSTANCE OF INTERVIEW DESCRIBING THE GEN	SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:						
Part III.	a warned of the substance of th	o interview, since the interview					
 ☑ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability. ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above. 							
Anne-Marie Falk	Anne-Marie Falk						
ANNE-MARIE FALK, PH.D							
PRIMARY FXAMINED (Examiner/SPE Signature) (Applic	ant/Applicant's Representative S	Signature – if appropriate)					